Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study.

Akshay N GuptePavan KumarMariana Araújo-PereiraVandana KulkarniMandar ParadkarNeeta PradhanPradeep MenonPadmapriya Darasini ChandrasekaranLuke-Elizabeth HannaShri Vijay Bala Yogendra ShivakumarNeesha RockwoodElsa Du BruynRajesh KaryakarteSanjay GaikwadRobert BollingerJonathan E GolubNikhil GupteVijay ViswanathanRobert J WilkinsonVidya MaveSubash BabuHardy KornfeldBruno B AndradeAmita Gupta

Published in: The European respiratory journal (2021)

Pre-treatment IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes. Future studies should identify optimal IL-6 concentrations for point-of-care risk prediction.

Keyphrases

mycobacterium tuberculosis
pulmonary tuberculosis
small molecule
emergency department
current status
adverse drug
replacement therapy